Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

Abstract: This invention relates to novel compounds according to Formula (I) which are antagonists of MrgX2, to pharmaceutical compositions containing them, and to their use in therapy for the treatment of MrgX2-mediated diseases and disorders.

Abstract: Various of the disclosed embodiments relate to systems and methods for providing animated multimedia, e.g. animated shows, to an audience over a network. Particularly, some embodiments provide systems and methods for generating and providing audio, animation, and other experience-related information so that user's may readily experience the content in a seamless manner (e.g., as an audience member watching a show, playing a video game, etc.). Various embodiments animate “to the audience” based, e.g., on what content the audience is consuming. The animations may be generated in real-time from constituent components and assets in response to user behavior.

Abstract: Various of the disclosed embodiments relate to systems and methods for providing animated multimedia, e.g. animated shows, to an audience over a network. Particularly, some embodiments provide systems and methods for generating and providing audio, animation, and other experience-related information so that user's may readily experience the content in a seamless manner (e.g., as an audience member watching a show, playing a video game, etc.). Various embodiments animate “to the audience” based, e.g., on what content the audience is consuming. The animations may be generated in real-time from constituent components and assets in response to user behavior.

Abstract: Various of the disclosed embodiments relate to systems and methods for providing animated multimedia, e.g. animated shows, to an audience over a network. Particularly, some embodiments provide systems and methods for generating and providing audio, animation, and other experience-related information so that user's may readily experience the content in a seamless manner (e.g., as an audience member watching a show, playing a video game, etc.). Various embodiments animate “to the audience” based, e.g., on what content the audience is consuming. The animations may be generated in real-time from constituent components and assets in response to user behavior.

Abstract: Various of the disclosed embodiments relate to systems and methods for providing animated multimedia, e.g. animated shows, to an audience over a network. Particularly, some embodiments provide systems and methods for generating and providing audio, animation, and other experience-related information so that user's may readily experience the content in a seamless manner (e.g., as an audience member watching a show, playing a video game, etc.). Various embodiments animate “to the audience” based, e.g., on what content the audience is consuming. The animations may be generated in real-time from constituent components and assets in response to user behavior.

Abstract: The present invention provides a crystalline form of a substantially pure constitutive androstane receptor (CAR) polypeptide. Also provided is a crystalline form of a substantially pure constitutive androstane receptor (CAR) polypeptide in complex with a ligand. Also provided are methods for generating the crystalline forms of the present invention and methods for identifying and designing CAR ligands and modulators. Also provided are scalable three-dimensional configurations of points and computer readable storage media containing digitally encoded structural data.

Abstract: The invention relates to a compound of formula (I): wherein all variables are as defined herein and to pharmaceutical compositions, methods of using, and processes for preparing the same.

Abstract: The invention relates to a compound of formula (I), wherein all variables are as defined herein, and pharmaceutically acceptable salts or solvates thereof. The compounds of formula (I) are useful as LXR agonists.